Phospholipid scramblase 1 (PLSCR1) is a multiply palmitoylated protein which is localized in either the cell membrane or nucleus depending on its palmitoylated state. The increasing evidence showed the biological roles of PLSCR1 in cell signaling, maturation and apoptosis. To investigate the functions of PLSCR1 in leukemic cells, we generated an inducible PLSCR1-expressing cell line using myeloid leukemic U937 cells. In this cell line, PLSCR1 was tightly regulated and induced upon tetracycline withdrawal. Our results showed that inducible PLSCR1 expression arrested the proliferation of U937 cells at G 1 phase. Meanwhile, PLSCR1-overexpressing U937 cells also underwent granulocyte-like differentiation with increased sensitivity to etoposide-induced apoptosis. Furthermore, we also found that PLSCR1 induction increased cyclin-dependent kinase inhibitors p27
Introduction
Hematopoiesis is a linear and hierarchical process that generates terminally differentiated blood cells from multipotential hematopoietic stem cells in the bone marrow. As documented, hematopoietic differentiation is an exquisitely regulated event, in which many transcription factors such as acute myeloid leukemia 1 (AML1), PU.1 and CCAAT/enhancer-binding proteins (C/EBPs) play critical roles (Yamanaka et al., 1998; Friedman, 2002; Mitani, 2004; Koschmieder et al., 2005) . It is leukemia that results from the acquisition by hematopoietic progenitors of hematopoietic gene mutations that confer deregulated proliferation, impaired differentiation and survival advantage (Yamanaka et al., 1998) .
Phospholipid scramblase 1 (PLSCR1) is a multiply palmitoylated protein originally identified based on its capacity to promote accelerated transbilayer phospholipid movement in response to Ca 2 þ (Basse et al., 1996; Zhao et al., 1998) . Although its role in membrane phospholipid scrambling is controversial, the increasing evidence showed that PLSCR1 has the biological significances in cell signaling, maturation and apoptosis. As it was reported in 2002 that proliferation and terminal differentiation of myeloid precursor cells in response to selective growth factors are impaired in PLSCR1 À/À mice , the potential roles of PLSCR1 in hematopoiesis and leukemogenesis began to be explored, but a little progress has been achieved. More recently, leukemic cell differentiation-inducing agents all-trans retinoic acid (ATRA) and phorbol 12-myristate 13-acetate (PMA) are shown to induce PLSCR1 expression through mediation of activated protein kinase C (PKC) d protein (Nakamaki et al., 2002; Zhao et al., 2004 Zhao et al., , 2005 . More especially, the suppression of PLSCR1 expression by small interfering RNA inhibits ATRA/PMA-induced leukemic cell differentiation (Zhao et al., 2004) , suggesting that PLSCR1 might contribute to leukemic cell differentiation.
In an attempt to investigate the biological functions of PLSCR1 in leukemic cells, this work established an inducible PLSCR1-expressing cell line U937 plscr1 using human AML cells, in which PLSCR1 is tightly regulated and induced only upon tetracycline withdrawal at both mRNA and protein levels. Our results showed that PLSCR1 presented antileukemic function by inducing growth arrest, triggering differentiation and amplifying etoposide-induced apoptosis. Complementary to these cytological effects is that PLSCR1 induction also increases p27 Kip1 
/p21
Cip1 and decreases c-Myc and Bcl-2 proteins, although their molecular mechanisms remain to be resolved. Taken together, our results would shed new insights into understanding the roles of PLSCR1 in hematopoiesis and leukemogenesis.
Results

Establishment of myeloid cell line with inducible PLSCR1 expression
To generate inducible PLSCR1-expressing U937 cell line, the full-length plscr1 cDNA was inserted into plasmid pTRE2hyg, a tetracycline-responsive expression vector, to form pTRE2hyg-plscr1. Then, pTRE2hyg-plscr1 and empty vector pTRE2hyg were, respectively, transfected into the U937T cells, which contain stably transfected pUHD-tTA (tetracycline-responsive transcription activator), whose expression is under the control of tetracycline (Boer et al., 1998) . In principle, the expression of tTA and PLSCR1 should be extremely low in the culture medium with tetracycline. On the contrary, tTA activates its own promoter to produce more tTA in the absence of tetracycline, latter activating PLSCR1 expression. Here, U937T cells stably transfected with pTRE2hyg-plscr1 and pTRE2hyg were respectively named as U937 plscr1 and U937 empty cells. To test the inducibility of PLSCR1 expression, the transfected cells were incubated in the presence and absence of 1 mg/ml tetracycline. The results showed that U937 plscr1 but not U937 empty cells were induced to express plscr1 mRNA and protein upon withdrawal of tetracycline, as determined by real-time quantitative reverse transcription (RT)-polymerase chain reaction (PCR) (data not shown) and Western blot ( Figure 1a ). As shown in Figure 1a , PLSCR1 protein began to increase at day 2 and reached maximum at day 4 after tetracycline removal in U937 plscr1 cells. Furthermore, immunofluorescent staining showed that over 90% of U937 plscr1 cells highly expressed PLSCR1 protein (Figure 1b) . In order to understand the subcellular distributions of inducible expressed PLSCR1 protein, we fractionated nuclei and cytoplasm/membrane of U937 plscr1 and U937 empty cells in the absence of tetracycline for 0, 3 and 5 days. The results revealed that inducible PLSCR1 protein was predominantly localized outside nuclei with little nuclear distribution (Figure 1c) , which was consistent with that seen under immunofluorescent microscope (Figure 1b ). Of note, nuclear PLSCR1appeared to have the same molecular weight as cytoplasmic PLSCR1.
Inducible PLSCR1 expression causes growth arrest at G 1 phase of U937 cells As depicted in Figure 2a , the cell proliferation was progressively inhibited in U937 plscr1 cells upon tetracycline removal, compared to that in U937 empty cells. In brief, the inhibition began to appear on day 4, and
whole cells nuclei (E, U937 empty ; P, U937 plscr1 ) were detected by Western blot analysis for PLSCR1 protein with b-actin and lamin B as controls.
reached the maximum (78.474.6% of inhibition) on day 12 after tetracycline removal. Consistent with this was that G 1 -phased cells presented progressive increase with the reduction of S-phased cells after tetracycline removal in U937 plscr1 cells but not in U937 empty cells (Figure 2b  and c) . These results suggest that PLSCR1 expression induces growth arrest at G 1 phase of leukemic U937 cell line.
Inducible expression of PLSCR1 triggers leukemic cells to undergo differentiation
We also tested whether inducible PLSCR1 expression directly induces leukemic cell differentiation, with ATRA-treated U937 empty /U937 plscr1 in tetracycline and NB4 cells as positive controls. Consistent with previous reports (Nakajima et al., 1996) , ATRA at 10
empty /U937 plscr1 cells to differentiate towards granulocytes in morphology, together with increased CD11c but not CD14 expression and without significant nitroblue tetrazolium (NBT) reducing activity (Figure 3) . Following withdrawal of tetracycline for 5-6 days, as can be seen in Figure 3a , U937 plscr1 cells exhibited mature granulocytic cell-associated morphological changes, such as smaller volume, reduced nucleo-cytoplasmic ratio, condensed chromatin, the disappearance of nucleoli with distorted and horse-shoe-shaped nuclei. Similar to ATRA-treated U937 empty /U937 plscr1 cells, accordingly, PLSCR1 overexpression also time-dependently induced expression of the differentiationassociated cell surface marker CD11c, but not CD14 (Figure 3b ), the latter being primarily the marker of monocytic differentiation (Nakajima et al., 1996) . Moreover, PLSCR1 expression failed to increase the NBT response, which was the case in ATRA-treated U937 empty /U937 plscr1 cells but not in ATRA-treated NB4 cells (Figure 3c ), indicating this was not owing to problems in technology. Finally, we also measured mRNA levels of neutrophil cytosolic factor-1 (NCF1), interleukin-1 receptor antagonist (IL1RN), orosomucoid 1 (ORM1) and secreted phosphoprotein 1 (SPP1) genes, given that these mRNAs were proposed to be used as leukemic cell differentiation signatures (Stegmaier et al., 2004) . As shown in Figure 3d , all four mRNA levels were significantly elevated when NB4 cells were treated with 10 À6 M of ATRA for 3 days, whereas ATRA-treated U937 plscr1 and U937 empty cells only presented increased expressions of SPP1 and NCF-1 with a little increase of IL1RN. The expressions of IL1RN and NCF1 were upregulated in U937 plscr1 cells but not in U937 empty cells, whereas expressions of SPP1 and ORM1 were not detected in both U937 plscr1 and U937 empty cells after withdrawal of tetracycline. Notably, increased expressions of CD11c, IL1RN and NCF1 preceded significant maturation-related morphological features, because alterations of expressions of these genes began to appear at day 3 after tetracycline removal. Collectively, all these results support that inducible PLSCR1 expression prompts leukemic cells to undergo differentiation towards granulocyte-like cells.
PLSCR1 regulates expression of cell cycle and differentiation-related genes To further analyse the molecular components involved in the induction of growth arrest and differentiation of U937 plscr1 cells, we examined some critical cell cycle and differentiation-regulating genes. The results showed that PLSCR1 induction failed to modulate p27
Kip1 mRNA level (Figure 4a ), but it progressively increased p27 Kip1 protein from day 3 after tetracycline withdrawal in U937 plscr1 cells (Figure 4b ), a time point later than PLSCR1 induction. Moreover, cycloheximide inhibition test demonstrated that the degradation of p27
Kip1 protein in U937 plscr1 upon PLSCR1 induction was slower than Kip1 degradation. We also tested the possible change of p21 Cip1 expression. Unlike p27 Kip1 , the mRNA level of this CDK inhibitor was also greatly increased in U937 plscr1 cells after PLSCR1 induction ( Figure 4a ). Correspondingly, increased p21
Cip1 protein could also clearly be seen at day 2 after tetracycline removal ( Figure 4b ). U937 empty cells had undetectable p21
Cip1 protein, but the half-life of p21 Cip1 protein appeared to be far longer in the presence of PLSCR1 induction than 1 h reported previously (Coleman et al., 2003) (Figure 4c ). Moreover, inducible PLSCR1 expression also significantly reduced mRNA (data not shown) and protein ( Figure 4b ) of S phase kinase-associated protein 2 (SKP2) in U937 plscr1 cells, which began to appear at day 3 and became more significantly from then on. We also examined AML1, PU.1 and C/EBPa proteins, several transcriptional factors critical for leukemic cell differentiation (Yamanaka et al., 1998; Friedman, 2002; Mitani, 2004; Koschmieder et al., 2005) . However, our results showed that PLSCR1 failed to change their protein levels (data not shown). More intriguingly, PLSCR1 expression significantly inhibited c-Myc mRNA and protein expression ( Figure 4b and data not shown).
Inducible PLSCR1 expression enhances etoposideinduced apoptosis Finally, expressions of some apoptosis-related genes such as bcl-2, bak, apaf-1 and mcl-1 were also studied with this inducible PLSCR1-expressing cell line. The results showed that antiapoptotic Bcl-2 protein was progressively reduced after tetracycline removal, which It has been well known that catalytic activity of PKCd is required, at or before the level of the mitochondria, for etoposide-induced apoptosis (Reyland et al., 1999; Matassa et al., 2001) . Furthermore, PKCd directly interacts with mitochondria and alters mitochondrial function for apoptosis induction (Li et al., 1999) . Vice versa, activated caspase-3 has amplifying effect on PKCd activation (Song et al., 2005) . Thus, we continued to analyse proteolytic activation of PKCd and caspase-3 as well as the cleavage of poly(ADP ribose) polymerase (PARP), a common substrate of activated caspase-3. As depicted in Figure 7a , 1.25 mM etoposide treatment for 24 h significantly induced proteolytic cleavage of PKCd protein together with activation of caspase-3 and cleavage of PARP in U937 plscr1 cells with PLSCR1 induction, whereas these changes could not be seen in
U937
empty cells with or without tetracycline removal. Immunofluorescent analysis with antibody only recognizing active caspase-3 also supported enhanced caspase-3 activation upon PLSCR1 induction (Figure 7c ). Furthermore, etoposide at 2.5 mM also induced activation of PKCd and caspase-3 as well as fragmentation of PARP in U937 empty cells, whereas these apoptosis-related alterations became more significant in PLSCR1-expressing U937 plscr1 cells (Figure 7a) . Furthermore, the time course analysis with 1.25 mM of etoposide (Figure 7b) showed that proteolytic cleavage of PKCd, activated , whereas these changes could be clearly seen at as early as 12 h in U937 plscr1 cells.
Discussion
Based on the potential role of PLSCR1 in ATRA/PMAinduced leukemic cell differentiation (Nakamaki et al., 2002; Zhao et al., 2004) , in this work, we generated an inducible human PLSCR1-expressing myeloid leukemic U937 plscr1 cell line. This cell line presented the advantage of not having been directly selected for PLSCR1 expression during its establishment. As such, it had not been preselected with particular features such as reduced proliferation or enhanced differentiation/apoptotic potential before the analysis of PLSCR1 expression. In U937 plscr1 cells, PLSCR1 was tightly regulated and induced only upon tetracycline withdrawal at both mRNA and protein levels. By using the cell line, we examined the biological significances of PLSCR1 in leukemic cells. Our results showed that, upon PLSCR1 induction, the proliferation of U937 plscr1 cells was arrested at G 1 phase of the cell cycle. Of note, the growth failed to be completely stopped although a longer cultivation was given, which was possibly because less than 10% cells did not express higher PLSCR1 protein in U937 plscr1 cell pool, as seen in immunofluorescent staining. More importantly, PLSCR1 overexpression alone could also drive leukemic U937 cells to undergo differentiation towards granulocyte-like cells, as determined by morphology, differentiation markers and differentiation-related gene expressions. These results provide direct evidence for the role of PLSCR1 in leukemic cell differentiation. Additionally, PLSCR1 induction also increased cellular sensitivity to etoposideinduced apoptosis. These findings suggest that PLSCR1 plays antagonistic role regarding leukemia/cancer development. Such a contention could also be supported at least by several lines of evidence as recently reported: First, de novo expression of a murine plscr1-truncated mutant (also called TRA1 or MmTRA1a) appeared in a monocytic leukemia cell line, and transfection of TRA1 converted non-leukemogenic cells into leukemogenic cells, as determined by studying survival after transplantation into syngenic or athymic mice (Kasukabe et al., 1997 (Kasukabe et al., , 1998 . It is noteworthy that the exogenous TRA1 expression did not influence in vitro growth rates of mouse monocytic and immortalized Mm-1 cells (Kasukabe et al., 1997) , suggesting that wild-type PLSCR1 presents different effects on the in vitro cell growth from its leukemogenic mutant TRA1. Secondly, the PLSCR1 mRNA in some AML patients, especially AML-M1 and AML-M5, was significantly lower than that in normal bone marrow cells. Furthermore, higher PLSCR1 mRNA level was associated with significantly longer overall survival in AML, especially in AML-M4 patients (Yokoyama et al., 2004) . Finally, stably overexpressing PLSCR1 in Chinese hamster ovary (CHO) K1 cell line (Yu et al., 2003) and human ovarian cancer cell line HEY1B (Silverman et al., 2002) Antileukemic roles of phospholipid scramblase 1 gene Y Huang et al basal level of cell death, along with increased sensitivity to ultraviolet (UV) irradiation-induced apoptosis in CHO-K1 cells, whereas it did not impact in vitro growth rate or morphology in HEY1B cells. However, stably overexpressing PLSCR1 did suppress in vivo growth of transplanted HEY1B in athymic nude mice (Silverman et al., 2002) .
Cell proliferation, differentiation and apoptosis are closely and subtly regulated by a series of gene expression programs. Physiologic regulation of the G 1 -S transition is critical during determination of cell fate. In order to provide the important insights for understanding the molecular mechanisms of biological functions of PLSCR1, we examined expressions of several critical genes related to cell growth, differentiation and apoptosis. Among these, p27
Kip1 and p21
Cip1
, two important and widely studied cyclin-dependent kinase inhibitors (CKIs), have been proposed to exert redundant functions in cell cycle progression and differentiation programs (Sherr and Roberts, 1999) . During the hematopoietic differentiation program, both CKIs are upregulated by multiple agents that trigger myeloid, megakaryocytic and erythroid differentiation (Steinman, 2002) . Overexpression of p27
Kip1 or p21 Cip1 in cell lines induces leukemic cell differentiation (Kikuchi et al., 1997; Rots et al., 1999) , whereas suppression of these CKIs by antisense techniques decreases myeloid differentiation (Wang et al., 1998) . Recently, MunozAlonso et al. (2005) reported that in addition to arresting proliferation, conditionally expressed p27 Kip1 and p21
Cip1 in K562, a multipotent human leukemic cell line, promoted differentiation towards megakaryocytic maturation or erythroid cells. Consistent with this is that absence of p27
Kip1 or p21 Cip1 affects the proliferation/differentiation balance of hematopoietic progenitors (Cheng et al., 2000) . Here, we showed that PLSCR1 induction significantly elevated p27 Kip1 protein by inhibiting its degradation. Moreover, PLSCR1 overexpression also increased p21
Cip1 protein by increased transcription and reduced degradation. It has been reported that the degradations of these two CKIs are regulated by SKP2, an F-box subunit of the ubiquitinligase complex that targets proteins for degradation (Carrano et al., 1999) . More intriguingly, PLSCR1 induction also decreased SKP2 mRNA and protein levels, although it was a little later than increase of p21 Cip1 proteins. According to these results, PLSCR1-reduced p27 Kip1 
/p21
Cip1 protein degradation was, at least partially, associated with downregulated SKP2 protein.
In addition to increased p27 Kip1 and p21 Cip1 proteins, the most significant molecular alteration upon PLSCR1 induction was the reduction of c-Myc protein, a basic helix-loop-helix (HLH) leucine zipper protein that dimerizes with its partner Max to activate gene transcription through consensus E-box elements located on the promoters of certain genes. This alteration could also support the differentiation-inducing effects of PLSCR1 to a degree, because it has been widely confirmed that both c-Myc mRNA and protein levels are virtually undetectable in terminally differentiated cells (Gonda and Metcalf, 1984; Larsson et al., 1994) . As well documented, dysregulated c-Myc expression is implicated in the development of multiple types of cancers including leukemia (Colby et al., 1983) . To date, several lines of evidence indicate that downregulation of c-Myc is a critical event for a cell, particularly myeloid cell, to commit to a differentiation pathway (Coppola and Cole, 1986) . Furthermore, treatment of myeloid cell empty and U937 plscr1 cells were treated with 2.5 mM of etoposide for 24 h. Active caspase-3 protein was detected by immunofluorescent staining with antibody that only recognizes active caspase-3 (upper panels) and cells were doubly stained by DAPI (lower panels).
Antileukemic roles of phospholipid scramblase 1 gene Y Huang et al lines with antisense oligonucleotides against c-Myc expression induces myeloid cell differentiation (Hoffman-Liebermann and Liebermann, 1991; Holt et al., 1998) . By the way, C/EBPa directly affects the level of cMyc expression and, thus, the decision of myeloid blasts to enter into the granulocytic differentiation pathway (Johansen et al., 2001 ). Combined with data described above, we assumed that increased p27 Kip1 
Cip1 proteins and reduced cMyc protein could contribute to PLSCR1-induced growth arrest and differentiation induction. As mentioned above, CHO-K1 cells overexpressing PLSCR1 showed higher basal level of cell death and amplified UV-induced apoptosis (Yu et al., 2003) , which was possibly mediated primarily by enhancement of the intrinsic apoptotic pathway (Yu et al., 2003; Bailey et al., 2005) . Here, we showed that PLSCR1 induction failed to increase basal level of apoptotic cells in U937T cells, but it did amplify etoposide-induced proteolytic cleavage of PKCd, the DC m collapse, caspase-3 activation, apoptotic nuclear changes and PARP cleavage. These results strongly indicate that PLSCR1 can enhance intrinsic pathway-induced apoptosis. Parallel to these apoptosis-featured alterations, PLSCR1 induction significantly reduced Bcl-2 protein, an important antiapoptotic factor, which possibly contributed to the amplified effects for etoposide-induced apoptosis under PLSCR1 induction.
Taken together, our results showed that PLSCR1 induction can arrest proliferation, induce differentiation and amplify etoposide-induced apoptosis, which could involve increased p27 Kip1 
Cip1 and decreased c-Myc and Bcl-2 proteins. The exact mechanism by which PLSCR1 regulates the expressions of these proteins remains unresolved. Biochemically, PLSCR1 was proposed to be a lipid-raft-associated endofacial plasma membrane protein, which is phosphorylated by selective protein kinases such as c-Abl, c-Src and PKCd that participate in multiple growth factor receptor signaling pathways (Frasch et al., 2000; Sun et al., 2001 Sun et al., , 2002 Nanjundan et al., 2003) . More recently, the nonpalmitoylated PLSCR1 was found to traffic into the nuclei via the non-classical nuclear localization signal (Ben-Efraim et al., 2004; Chen et al., 2005) . In the nucleus, PLSCR1 tightly binds to sequence GTAAC CATGTGGA in the promoter region of the inositol 1,4,5-triphosphate receptor type 1 gene to enhance expression of the receptor . Bioinformatics analysis did not find such a PLSCR1-binding site in the promoters of p21 cip1 , SKP2, c-Myc and bcl-2. On the other hand, inducible PLSCR1-expressing protein was predominantly localized outside the nuclei in our inducible cell system. Based on these facts, we speculate that the cytosolic PLSCR1 might be responsible for PLSCR1 overexpression-induced cellular and molecular effects in leukemic cells as described in this work. Of course, we can not completely exclude a possible contribution of the nuclear PLSCR1 to these events. To resolve this question, the effects of the palmitoylated site-mutated PLSCR1 (only expression in nuclei) and nuclear localization signal-mutated PLSCR1 (only expression in cytosol) (Chen et al., 2005) on leukemic cells deserve to be further observed in the future.
In summary, this work indicates that PLSCR1 exerts antileukemic effects by inducing growth arrest, differentiation and apoptosis. Further works on roles of PLSCR1 on leukemic cells and possible genetic/epigenetic alterations of PLSCR1 in patients with leukemia will become interesting subjects.
Materials and methods
Cell lines
Human myeloid leukemic cell lines NB4 and U937 cells were cultured in RPMI-1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Gaithersburg, ML, USA) at 371C in 5% CO 2 . U937T cells (kindly provided by Dr DG Tenen in Harvard Institutes of Medicine, Harvard Medical School, Boston, MA, USA) (Boer et al., 1998) are U937 cells stably transfected with a pUHDtTA under the control of a tetracycline-inducible promoter. U937T cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 1 mg/ml of tetracycline (Sigma) and 0.5 mg/ ml of puromycin (Sigma). Cell viability was determined by the trypan-blue exclusion assay.
Establishment of U937
plscr1 stable transformant Full-length plscr1 cDNA, which was isolated from pFLAG-CMV4-plscr1 constructed from pcDNA3-plscr1, was subcloned into NotI and EcoRV of pTRE2hyg expression vector (BD Clontech, Palo Alto, CA, USA) to form pTRE2hyg-plscr1 plasmid. The sequence of the cDNA insert of the plasmid was confirmed by sequencing. To generate U937 plscr1 stable transformant, 1 Â 10 7 of U937T cells were washed in RPMI 1640-medium and resuspended in 0.2 ml of Isceve's Modified Dulbecco's medium without FBS. Twenty micrograms of pTRE2hyg-plscr1 or empty plasmid pTRE2hyg in 20 ml ddH 2 O was transferred to electroporation cuvette with a 0.4 cm gap (Bio-Rad, Hercules, CA, USA). Electroporation was performed using a Gene-Pulser II (Bio-Rad) at 170 V and 960 mF. The samples were then transferred to complete RPMI-1640 medium. Twenty-four hours later, 1 mg/ml of tetracycline, 0.5 mg/ml of puromycin and 500 mg/ml of hygromycin B (BD Clontech) were added and cells were continued to incubate at 371C in 5% CO 2 . Positive polyclonal population (pool) was identified based on the induction of PLSCR1 expression following tetracycline withdrawal and was named U937 plscr1 . As a control, empty plasmid-transfected cell line was called U937 empty . U937 plscr1 and U937 empty cells were maintained in RPMI-1640 medium supplemented with 10% FBS, and 1 mg tetracycline, 0.5 mg puromycin and 0.5 mg hygromycin B/ml.
Quantitative and semiquantitative RT-PCR Total RNA was extracted from cells by TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and RT was performed by Promega RNA PCR kit (Promega, Madison, WI, USA) following manufacturer's instructions. Fluorescence real-time quantitative RT-PCR was performed as we previously described (Zhao et al., 2004) , with specific primers as indicated in Table 1 . The folds of changes were shown as means7s.d. in three independent experiments with each triplicate. For semiquantitative RT-PCR, PCR reactions to amplify differentiation-related genes NCF1, IL1RN, ORM1 and SPP1 and b-actin as internal control were performed, respectively, in a single tube using the Eppendorf Mastercycler (Eppendorf AG, Hamburg, Germany) with specific primers as shown in Table 1 . PCR consisted of 25-30 cycles with denaturing at 951C for 45 s, annealing at 56-581C for 45 s and extension at 721C for 45 s. Amplification cycles were preceded by a denaturation step (951C for 5 min) followed by an elongation step (721C for 10 min). After amplification, PCR products were analysed on a 1.5% agarose gel.
Cell cycle and apoptosis assay
The nuclear DNA content-related cell cycle distributions were determined by flow cytometry (Beckman Coulter, Miami, FL, USA) as described previously (Song et al., 2005) . All data were collected, stored and analysed by Multicycle software (Beckman Coulter). Annexin V assay was performed on a flow cytometry (Beckman Coulter) according to the instructions provided by the Annexin V-FITC (fluorescein isothiocyanate) Apoptosis Detection kit I (BD Pharmingen, San Diego, CA, USA). The mitochondrial transmembrane potentials (Dc m ) were decided according to fluorescent intensities of Rhodamine 123 (Rh123, Sigma) on flow cytometry as described previously (Song et al., 2005) .
Differentiation assay
For morphologic observation, cells were collected onto slides by cytospin (Shandon, Runcorn, UK), stained (Wright staining) and observed by light microscope (Olympus, BX-51, Tokyo, Japan). The images were captured with Olympus DP50 digital camera by Image-Pro plus. Differentiation antigens were measured using FITC-labeled anti-CD11c (Immunotech, Marseille, France) or phycoerythrin (PE)-labeled anti-CD14 antibodies (BD Pharmingen), as previously described (Jiang et al., 2005) . Simultest Control IgG1 (Immunotech) and IgG2a(r) (BD Pharmingen) were used as negative controls. Fluorescence intensities of FITC and PE were analysed by flow cytometry (Beckman Coulter). NBT reduction test was performed as described previously (Zhu et al., 1995) .
Immunofluorescent staining of cells Cells were collected onto slides by cytospin (Shandon) and fixed with 4% formaldehyde for 10 min. After permeabilizing by 0.3% Triton X-100 in PBS for 10 min, cells were incubated with 1% bovine serum albumin in PBS for 2 h at room temperature, followed by overnight incubation with antibody against PLSCR1 (4D2) or active caspase-3. Cells were stained with FITC-labeled anti-mouse IgG (Kangchen, Shanghai, China) or FITC-labeled swine anti-rabbit IgG (Dako A/S, Glostrup, Denmark) for 1 h. Cell nuclei were stained with 4 0 ,6-diamidino-2-phenylindole (DAPI, Molecular Probes, Eugene, OR, USA). Fluorescence signals were observed on a Bio-Rad MRC-1024 laser scanning confocal microscope equipped with a Zeiss Â 60 objective or fluorescence microscope (Olympus).
Nuclear and cytoplasmic fractionation Cells (about 1 Â 10 7 ) were incubated in 300 ml lysis buffer (10 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid), 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM dithiothreitol (DTT, pH 7.9) with the supplement of 0.2% Nonidet P-40 (NP-40) and protease inhibitor cocktail (Sigma) for 20 min on ice. The lysates were microcentrifuged for 1 min at 2300 g. The supernatants were collected as cytoplasmic protein extracts. Then, the pellets were washed with lysis buffer without NP-40 and resuspended in 150 ml extraction buffer (62.5 mM Tris-HCl, pH 6.8, 4% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% bromophenol blue) and incubated for 20 min on ice. The samples were centrifuged at 12 000 g for 10 min, and the supernatants were collected as nuclear protein extracts.
Cycloheximide inhibition test U937 plscr and U937 empty cells were grown in tetracycline-free medium for 4 days. Thereafter, cells were incubated with 30 mg/ml cycloheximide (Sigma) for additional time courses (0, 1, 2, 4, 8, 12 and 24 h). p27
Kip1 and p21 Cip1 proteins were measured by Western blots with b-actin as loading controls.
Western blots
Cell lysates were equally loaded to 10-12% SDS-polyacrylamide gel, electrophoresed and transferred to nitrocellulose membrane (Amersham Bioscience, Buckinghamshire, UK). The membranes were stained with 0.2% Ponceau S red to ensure equal protein loading. After blocking with 5% non-fat milk in PBS, the membranes were probed overnight with antibodies against PLSCR1 (4D2), Bak (NeoMarkers, Fremont, CA, USA), Bcl-2 (Dako A/S), p27
Kip1 (BD Pharmingen), p21
Cip1 , SKP2, Mcl-1, PKCd, lamin B, AML1, PU.1, C/EBPa (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Apaf-1, c-Myc, activated caspase-3 and PARP (Cell Signaling, Beverly, MA, USA). Then, the blots were incubated by horseradish peroxidase (HRP)-linked secondary antibody (Cell Signaling) for 1 h at room temperature. The signals were detected by chemiluminescence phototope-HRP kit (Cell Signaling) according to the manufacturer's instructions. As necessary, blots were stripped and reprobed with anti-b-actin (Oncogene, Fremont, CA, USA) as internal controls. All experiments were repeated three times independently with similar results.
Statistical analysis
Student's t-test was used to compare the difference between two different groups. A value of Po0.05 was considered to be statistically significant.
